A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Axon Enterprise, Inc. (NASDAQ:AXON), a leader in public safety technology with a market capitalization of over $50 billion, has been on a remarkable growth trajectory, driven by its expanding product ...

The flip side is the the market has become increasingly aware of what Axon has to offer, and the stock has skyrocketed. After hitting multiple all-time highs last year, the stock retreated in ...

Researchers don’t yet fully understand what causes multiple sclerosis (MS) but believe it may develop from a combination of genetic and environmental factors. Identifying these factors can help ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to severe ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of multiple sclerosis drugs including Teva's Copaxone. The health ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

The company’s lead product candidate, NB-4746 targets SARM1, a neuronally enriched nicotinamide adenine dinucleotide hydrolase that functions as a significant axon-intrinsic metabolic ... as ...

During his departure announcement in 2024, Neil thanked his bosses for their patience when he took off “a day or two here and there battling everything from multiple sclerosis and COVID to ...